SCIRENT, a full-service cardiovascular Contract Research Organization (CRO) specializing in clinical studies for heart failure and cardiac devices, will participate in the upcoming CSI Focus
A behind-the-scenes look at ESC 2025 in Madrid At this year’s European Society of Cardiology (ESC) Congress in Madrid, the spotlight was not only on cutting-edge research and
The ESC Heart Failure Congress in Belgrade this year was a truly special event for all of us at SCIRENT. Not only because it is
We’re excited to announce that SCIRENT, a leading Contract Research Organization (CRO) specializing in cardiovascular research, will be attending the American College of Cardiology’s Annual Scientific SessionACC.25, taking place
It’s early March, and as spring begins, we celebrate a special day that is even a public holiday in Berlin: International Women’s Day. This day
In clinical research, milestones like study initiation, patient recruitment, or the completion of data analysis are closely tied to investor payments. Funding for the next
As a leading Contract Research Organization specializing in cardiovascular research, SCIRENT is eager to join the THT Conference in Boston from February 11-13, 2025. This conference is a
At SCIRENT, we are excited to work for TargED Biopharmaceuticals B.V. in developing TGD001, an innovative thrombolytic therapy for thrombotic diseases. PEI Approval in Record
Join SCIRENT at the ESC Congress 2024 in London, where we continue to lead in cardiovascular clinical research. Discover our innovative approaches at booth F530 and explore how we personalize care to improve outcomes in cardiovascular health.
Imbria Pharmaceuticals’ Phase 2 IMPROVE-HCM trial showed significant improvements in symptoms and exercise performance for nHCM patients. The Radcliffe Department of Medicine at Oxford University played a crucial role in this successful trial.
Echocardiography is an indispensable tool in clinical trials, providing detailed insights into cardiac function and structure without invasive procedures. Echo Core Labs enhance the precision and reliability of these measurements by standardizing procedures across multiple trial sites, significantly reducing variability and improving data quality. This critical role not only supports better clinical outcomes but also ensures the accuracy necessary for developing new medical treatments.
In the rapidly evolving landscape of cardiovascular research, the strategic transition between Contract Research Organizations (CROs) is critical. This excerpt delves into the nuances of CRO transitions, highlighting the importance of meticulous planning, transparent communication, and the agility to adapt to new challenges. Understand the pivotal role that CROs play in advancing therapeutic innovations from concept to clinical reality, and explore the strategies that ensure these transitions strengthen, rather than hinder, the research continuum.
Phase 1 clinical studies are the initial step in drug development, designed to assess the safety and tolerability of a new molecule in humans. Traditionally investigational medicinal products (IMP) were tested in multiple Phase 1 clinical trials that enrolled large numbers of healthy participants before a first patient was randomized.
Insights into best practices and efficiency improvement in clinical trials highlight the importance of thorough site identification and selection in the field of cardiovascular research.
The industry spent over $200 billion globally in 2021 on developing new therapies for treating cardiovascular diseases. However, it’s estimated that more than half of
Maike, 32, and Nadja, 32, work as Clinical Research Associates (CRA) in medical research. They discuss what makes this job unique and why they enjoy
SCIRENT is excited to participate at the TCT Conference from October 23-26, 2023, in San Francisco. The Transcatheter Cardiovascular Therapeutics (TCT) conference, hosted by the
Roswell, Georgia – 9 October, 2023 – Roivios Ltd., a medical device company pioneering a revolutionary treatment to reduce poor surgical outcomes associated with Acute
SCIRENT will be participating in the renowned ESC Congress in Amsterdam from 25th to 28th August 2023. This prestigious event is a powerful platform for
Save the dates in your agenda and join us in Prague from 20 to 23 May 2023 for the ESC Heart Failure Association (HFA) annual meeting
SCIRENT is thrilled to announce that we will be attending several high-ranking cardiovascular conferences in 2023. Meet our team to discover how SCIRENT, a specialized
SCIRENT, a full-service contract research organization (CRO) specializing in cardiovascular trials, is joining forces with CCS, a US-based cardiovascular clinical research organization, at HFSA Annual Scientific
SCIRENT is excited to participate at the ESC Congress 2022 in Barcelona, which is taking place from 26-29 August 2022. Please book an appointment with
10.11.2021. SCIRENT is attending the American Heart Association’s Scientific Sessions, AHA 2021, from November 13-15, 2021 as a proud exhibitor. Visit our booth and connect
BERLIN, Sept. 21, 2021 /PRNewswire/ SCIRENT, an international full-service cardiovascular contract research organization (CRO), is proud to appoint Dr. Maximilian Posch as Chief Medical Officer.
Berlin Heals’ innovative implantable C-MIC device delivers encouraging clinical results in the treatment of heart failure.
The entire landscape of hospital-based clinical trials dramatically changed when COVID-19 singlehandedly stopped the global recruitment of ongoing cardiovascular trials. Heart failure clinical trials were
SCIRENT, a full-service contract research organization (CRO) specialized in cardiovascular trials, and Virtonomy, a pioneer in developing data-driven clinical trials using virtual patients, announced today
Global medical technology and innovation company, LivaNova PLC, conducts the large medical device study ANTHEM-HFrEF to evaluate whether autonomic regulation therapy will benefit patients with
Drug developer Berlin Cures has launched a phase IIa trial for its β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDNA product BC 007.
The global COVID-19 pandemic has largely impacted the healthcare system and also the conduct of clinical trials. Many sponsors have had to adapt clinical trial
